News

Sarepta initiated with a bullish view at Wells Fargo on Elevidys
Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial ...
Becker's Hospital Review3d
After patient’s death, study cites potential barrier to Elevidys
A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...
BioSpace7d
Committee Recommends EU Trials of Sarepta’s Elevidys Continue, Day After Holds
One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Setback in gene therapy for Duchenne muscular dystrophy as immune system emerges as key barrier
A new paper published in Gene Therapy raises serious concerns about the effectiveness of gene therapy for Duchenne muscular ...
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space
Explore Solid Biosciences’ potential with promising SGT-003 trial results for DMD, strong financials, and market recovery ...
Neurology Advisor9d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
BioPharma Dive8d
Roche halts testing of Sarepta Duchenne gene therapy in Europe
The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...
Sarepta initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...
Fierce Pharma8d
UPDATE: After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Benzinga.com8d
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Try it free for 7 days In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular ...